Health and Healthcare
Why One Analyst Sees Big Upside in This COVID-19 Vaccine Stock
Published:
BioNTech S.E. (NASDAQ: BNTX) was in the spotlight on Tuesday after it received a sizable price target hike from one key analyst. This German biotechnology company has been at the forefront in the fight against COVID-19 as it, along with Pfizer Inc. (NYSE: PFE), recently received approval for a coronavirus vaccine from the U.S. Food and Drug Administration (FDA).
The FDA authorized BioNTech and Pfizer’s mRNA COVID-19 vaccine, BNT162b2, and the Center for Disease Control (CDC) voted to recommend use. These companies have multiple supply agreements for 570 million doses. Considering this, one analyst decided to hike its target price.
Canaccord Genuity reiterated a Buy rating for BioNTech and raised its price target to $130 from $115, implying upside of 20% from the most recent closing price of $108.27.
In terms of the supply agreements, there are 570 million doses committed, plus an option on 600 million more. Here’s the breakdown: 200 million doses for the European Union, with an option for 100 million; 30 million doses for the United Kingdom; 100 million for the United States, with an option for 500 million; 120 million doses for Japan; 10 million for Hong Kong/Macau; and 110 million undisclosed in nine countries for 2020 to 2021 delivery.
As it stands now, Pfizer and BioNTech expect to manufacture 50 million doses in 2020 and up to 1.3 billion doses in 2021. The manufacturing guidance, however, was not increased, even following the acquisition of the Marbug facility, though management is working toward this contributing meaningfully in the second half of 2021.
The FDA panel voted that the “benefits outweigh the risk” in a 17-to-4 decision for BNT162b2 in use in 16+ year olds, in an Emergency Use Authorization (EUA). The CDC voted in favor of the EUA as well, and also that the initial supply would go to health care workers and nursing home residents.
BioNTech stock traded up about 3% on Tuesday to $111.11, in a 52-week range of $27.73 to $131.00. The consensus price target is $115.28.
Pfizer stock was down about 2%, at $38.38 in a 52-week range of $26.45 to $43.08. The consensus price target is $42.00.
24/7 Wall St.100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
